FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980152759> ?p ?o ?g. }

• W2980152759 abstract "Abstract Background CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of maturational stages and demonstrates death signaling via SHP1. Otlertuzumab is a CD37-specific therapeutic protein built on the ADAPTIR™(modular protein technology) platform that has shown significantly greater direct killing of CLL cells than rituximab and higher levels of Fc-mediated cellular cytotoxicity of CLL cells than either alemtuzumab or rituximab in pre-clinical models. This phase 1b trial was conducted to evaluate the safety and efficacy of otlertuzumab in combination with rituximab in patients with previously untreated CLL. Methods Patients with untreated CLL that required treatment, had adequate organ function, ECOG ≤2, and absolute neutrophil count ≥800/μL were eligible. Patients were ineligible for chemotherapy as first-line therapy due to patient age, comorbidity, or patient refusal of chemotherapy Patients received otlertuzumab (20 mg/kg) weekly by IV infusion for two 28-day cycles then once a month for 4 months. Rituximab (375 mg/m2 the first dose then 500 mg/m2) was administered after otlertuzumab by IV infusion on the same schedule. Safety was evaluated using CTCAE and IWCLL 2008 Grading scale for Hematologic Toxicity in CLL Studies. Response was determined using the 1996 NCI and the 2008 IWCLL Criteria. Results 24 patients have been treated. Patient characteristics and adverse events are shown in the table. The majority of the patients have not completed 6 cycles of therapy. The preliminary response by investigator assessment using NCI criteria at the last assessment is an ORR 88% (21/24); 2 patients have had PD. Six patients have had CT scans and bone marrow assessments 3 months after their last dose of study drug; by IWCLL criteria 1 has a CR, 4 have a PR and 1 has SD. The patient with a CR was MRD negative by five color flow cytometry of bone marrow aspirate. One patient discontinued therapy for a systemic inflammatory response. Severe (Grade 3 or 4) neutropenia was reported in 13% of patients; the incidence of severe infections was low (8%). Serious adverse events were reported for 4 patients: pneumonia, systemic inflammatory response, and deep vein thrombosis in 1 patient; and lymph node pain, worsening sinusitis, and fever in 1 patient each. Conclusions The preliminary response rate with otlertuzumab in combination with rituximab is promising. Follow-up is ongoing and the IWCLL response rate will be presented. Disclosures: O'Brien: Emergent Product Development: Research Funding. Stromatt:Emergent Biosolutions: Employment. Awan:Lymphoma Research Foundation - Research Funding: Research Funding, Speakers Bureau; Spectrum Pharmaceuticals, Inc. - Speakers bureau: Research Funding, Speakers Bureau." @default.
• W2980152759 created "2019-10-18" @default.
• W2980152759 creator A5000921376 @default.
• W2980152759 creator A5006104041 @default.
• W2980152759 creator A5024389256 @default.
• W2980152759 creator A5040412322 @default.
• W2980152759 creator A5059854479 @default.
• W2980152759 creator A5078642863 @default.
• W2980152759 date "2013-11-15" @default.
• W2980152759 modified "2023-10-12" @default.
• W2980152759 title "Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)" @default.
• W2980152759 doi "https://doi.org/10.1182/blood.v122.21.4165.4165" @default.
• W2980152759 hasPublicationYear "2013" @default.
• W2980152759 type Work @default.
• W2980152759 sameAs 2980152759 @default.
• W2980152759 citedByCount "0" @default.
• W2980152759 crossrefType "journal-article" @default.
• W2980152759 hasAuthorship W2980152759A5000921376 @default.
• W2980152759 hasAuthorship W2980152759A5006104041 @default.
• W2980152759 hasAuthorship W2980152759A5024389256 @default.
• W2980152759 hasAuthorship W2980152759A5040412322 @default.
• W2980152759 hasAuthorship W2980152759A5059854479 @default.
• W2980152759 hasAuthorship W2980152759A5078642863 @default.
• W2980152759 hasConcept C126322002 @default.
• W2980152759 hasConcept C143998085 @default.
• W2980152759 hasConcept C197934379 @default.
• W2980152759 hasConcept C2776694085 @default.
• W2980152759 hasConcept C2776755627 @default.
• W2980152759 hasConcept C2777063308 @default.
• W2980152759 hasConcept C2777938653 @default.
• W2980152759 hasConcept C2778461978 @default.
• W2980152759 hasConcept C2778594517 @default.
• W2980152759 hasConcept C2779015954 @default.
• W2980152759 hasConcept C2779263901 @default.
• W2980152759 hasConcept C2779338263 @default.
• W2980152759 hasConcept C2779788671 @default.
• W2980152759 hasConcept C2780653079 @default.
• W2980152759 hasConcept C2781442060 @default.
• W2980152759 hasConcept C2911091166 @default.
• W2980152759 hasConcept C71924100 @default.
• W2980152759 hasConcept C90924648 @default.
• W2980152759 hasConceptScore W2980152759C126322002 @default.
• W2980152759 hasConceptScore W2980152759C143998085 @default.
• W2980152759 hasConceptScore W2980152759C197934379 @default.
• W2980152759 hasConceptScore W2980152759C2776694085 @default.
• W2980152759 hasConceptScore W2980152759C2776755627 @default.
• W2980152759 hasConceptScore W2980152759C2777063308 @default.
• W2980152759 hasConceptScore W2980152759C2777938653 @default.
• W2980152759 hasConceptScore W2980152759C2778461978 @default.
• W2980152759 hasConceptScore W2980152759C2778594517 @default.
• W2980152759 hasConceptScore W2980152759C2779015954 @default.
• W2980152759 hasConceptScore W2980152759C2779263901 @default.
• W2980152759 hasConceptScore W2980152759C2779338263 @default.
• W2980152759 hasConceptScore W2980152759C2779788671 @default.
• W2980152759 hasConceptScore W2980152759C2780653079 @default.
• W2980152759 hasConceptScore W2980152759C2781442060 @default.
• W2980152759 hasConceptScore W2980152759C2911091166 @default.
• W2980152759 hasConceptScore W2980152759C71924100 @default.
• W2980152759 hasConceptScore W2980152759C90924648 @default.
• W2980152759 hasLocation W29801527591 @default.
• W2980152759 hasOpenAccess W2980152759 @default.
• W2980152759 hasPrimaryLocation W29801527591 @default.
• W2980152759 hasRelatedWork W126125533 @default.
• W2980152759 hasRelatedWork W2083928908 @default.
• W2980152759 hasRelatedWork W2127936842 @default.
• W2980152759 hasRelatedWork W2132877723 @default.
• W2980152759 hasRelatedWork W2260296716 @default.
• W2980152759 hasRelatedWork W2326926256 @default.
• W2980152759 hasRelatedWork W2336988007 @default.
• W2980152759 hasRelatedWork W2510562806 @default.
• W2980152759 hasRelatedWork W2524130482 @default.
• W2980152759 hasRelatedWork W2530738226 @default.
• W2980152759 hasRelatedWork W2547004112 @default.
• W2980152759 hasRelatedWork W2549783751 @default.
• W2980152759 hasRelatedWork W2551822051 @default.
• W2980152759 hasRelatedWork W2556995775 @default.
• W2980152759 hasRelatedWork W2560152574 @default.
• W2980152759 hasRelatedWork W2561647909 @default.
• W2980152759 hasRelatedWork W2587896352 @default.
• W2980152759 hasRelatedWork W2590111115 @default.
• W2980152759 hasRelatedWork W2907684934 @default.
• W2980152759 hasRelatedWork W3109434564 @default.
• W2980152759 isParatext "false" @default.
• W2980152759 isRetracted "false" @default.
• W2980152759 magId "2980152759" @default.
• W2980152759 workType "article" @default.